Sotera Health (NASDAQ:SHC) Receives $15.92 Consensus Target Price from Analysts

Sotera Health (NASDAQ:SHC) has received a consensus rating of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $15.92.

Several equities analysts recently commented on SHC shares. The Goldman Sachs Group started coverage on Sotera Health in a research note on Friday, December 6th. They issued a “neutral” rating and a $14.00 price objective on the stock. Barclays dropped their target price on Sotera Health from $17.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th.

Sotera Health Price Performance

Sotera Health stock opened at $11.90 on Wednesday. Sotera Health has a 12 month low of $10.71 and a 12 month high of $17.08. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91. The business’s 50 day simple moving average is $12.94 and its 200 day simple moving average is $14.15. The company has a market cap of $3.37 billion, a price-to-earnings ratio of 47.60 and a beta of 1.92.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System increased its stake in Sotera Health by 8.0% in the fourth quarter. California State Teachers Retirement System now owns 145,411 shares of the company’s stock valued at $1,989,000 after acquiring an additional 10,778 shares during the last quarter. Neo Ivy Capital Management increased its stake in Sotera Health by 144.7% in the fourth quarter. Neo Ivy Capital Management now owns 105,546 shares of the company’s stock valued at $1,443,000 after acquiring an additional 62,420 shares during the last quarter. Two Seas Capital LP increased its stake in Sotera Health by 624.0% in the fourth quarter. Two Seas Capital LP now owns 2,896,136 shares of the company’s stock valued at $39,619,000 after acquiring an additional 2,496,136 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Sotera Health by 14.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 299,463 shares of the company’s stock valued at $4,097,000 after acquiring an additional 37,468 shares during the last quarter. Finally, Vident Advisory LLC bought a new position in Sotera Health in the fourth quarter valued at $209,000. Institutional investors own 91.03% of the company’s stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.